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Abstract
Background: Current WHO testing guidelines for resource limited settings diagnose HIV on the basis of screening
tests without a confirmation test due to cost constraints. This leads to a potential risk of false positive HIV diagnosis.
In this paper, we evaluate the dilution test, a novel method for confirmation testing, which is simple, rapid, and low
cost. The principle of the dilution test is to alter the sensitivity of a rapid diagnostic test (RDT) by dilution of the
sample, in order to screen out the cross reacting antibodies responsible for falsely positive RDT results.
Methods: Participants were recruited from two testing centres in Ethiopia where a tiebreaker algorithm using 3
different RDTs in series is used to diagnose HIV. All samples positive on the initial screening RDT and every 10th
negative sample underwent testing with the gold standard and dilution test. Dilution testing was performed using
Determine™ rapid diagnostic test at 6 different dilutions. Results were compared to the gold standard of Western
Blot; where Western Blot was indeterminate, PCR testing determined the final result.
Results: 2895 samples were recruited to the study. 247 were positive for a prevalence of 8.5 % (247/2895). A total
of 495 samples underwent dilution testing. The RDT diagnostic algorithm misclassified 18 samples as positive.
Dilution at the level of 1/160 was able to correctly identify all these 18 false positives, but at a cost of a single false
negative result (sensitivity 99.6 %, 95 % CI 97.8-100; specificity 100 %, 95 % CI: 98.5-100). Concordance between the
gold standard and the 1/160 dilution strength was 99.8 %.
Conclusion: This study provides proof of concept for a new, low cost method of confirming HIV diagnosis in
resource-limited settings. It has potential for use as a supplementary test in a confirmatory algorithm, whereby
double positive RDT results undergo dilution testing, with positive results confirming HIV infection. Negative results
require nucleic acid testing to rule out false negative results due to seroconversion or misclassification by the lower
sensitivity dilution test. Further research is needed to determine if these results can be replicated in other settings.
Trial registration: ClinicalTrials.gov, NCT01716299.
Background
The diagnosis of HIV is made on the basis of a reactive
screening test or tests followed by a confirmation test.
However due to issues of cost, the WHO currently rec-
ommends that confirmation testing is not performed in
resource limited settings, and instead that diagnosis be
made on the basis of an algorithm employing 2–3 rapid
diagnostic tests (RDTs) [1]. This strategy has allowed
life-saving scale up of HIV diagnosis, as it permits test-
ing to be decentralized outside of the laboratory. The
compromise is that without a confirmation test, some
individuals will be falsely diagnosed as HIV positive.
This risk of false positive HIV diagnosis on the basis of 2
RDT positive results has been shown in a number of
settings with different RDTs [2–5]. The risk is increased
in lower prevalence populations. The mechanism causing
false positive reactions on serological tests is that of
non-HIV antibodies cross-reacting with the test anti-
gens [6]. Given the consequences for individuals in
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terms of the psychological impact, effect on family and
community, and possible health consequences of un-
necessary exposure to antiretroviral drugs, our group
has called for implementation of routine confirmation
testing [3]. However, the gold standard for confirmation
of HIV testing has been Western Blot (WB) or indirect
immunofluorescence assay (IFA) neither of which is
suitable for use in peripheral laboratories. Traditional
confirmation tests also have limitations in identifying
recent seroconversion, can give indeterminate results,
and do not allow discrimination between HIV 1 & 2 in-
fections. These limitations have led the US to introduce
new guidelines that employ a supplementary testing
algorithm rather than a single confirmation test [7, 8].
Samples repeatedly positive on screening assays, are
given a supplementary test to confirm infection, and if
negative go on to nucleic acid testing (NAT) to rule out
a false negative result due to early seroconversion. The
only supplementary test currently approved by the FDA
is Bio-Rad Multispot HIV-1/HIV-2 Rapid Test. It is a
single use flow-through rapid test that yields a result in
15 min., and is able to discriminate between HIV 1 & 2.
Bio-Rad Geenius HIV 1/2 Confirmatory Assay, is
another single use rapid test that is being evaluated as a
supplementary test but is not yet approved for this use
by the FDA. We are not aware of any published evalua-
tions done outside of reference laboratories of either
test and current pricing limits their use in resource-
limited settings. We use a low cost confirmation test
which we have shown is feasible for use in a peripheral
laboratory, the Orgenics Immunocomb® II, HIV 1&2
Combfirm or OIC. [3]. However this test is not CE
marked nor has it been evaluated by WHO. There is
therefore an urgent need to develop new confirmation
tests or methodologies that are low cost and feasible for
use in resource-limited settings.
In this paper, we describe a new methodology to
confirm positive HIV screening tests, using serial sample
dilution of RDTs. We postulate that by decreasing the
sensitivity of the HIV RDT through serially diluting the
sample, it will be possible to screen out false positive
samples, and correctly identify true positives.
The work reported here formed part of a larger study
on HIV diagnostics [9]. In Ethiopia, a tiebreaker regimen
consisting of 3 RDTs in series is the national algorithm.
HIV (1 + 2) Antibody Colloidal Gold (KHB, Shanghai
Kehua Bio-engineering Co Ltd, China) is used as a
screening test, followed by HIV 1/2 STAT-PAK® (Chembio
Diagnostics, USA) if positive. Where the result of STAT-
PAK® is discordant with KHB, a third test, Unigold HIV
(Trinity Biotech, Ireland), is used as a tiebreaker to deter-
mine the result. Médecins Sans Frontières-Holland (MSF),
in response to reported cases of false positive results [10],
uses an alternate algorithm in Ethiopia, consisting of two
RDTs (KHB, STAT-PAK®) in series, followed by the OIC
confirmation test. The primary objective of the study was
to evaluate the performance of these two algorithms. Sec-
ondary objectives, in addition to evaluating dilution testing,
were to evaluate the positive predictive value of weakly
reactive RDT test lines [9] and to determine if visceral
leishmaniasis (VL), a disease endemic in the region, was
associated with an increased risk of false positive reactions.
In this paper we focus on the dilution testing objective.
Methodology
Setting
The study was conducted in 2 sites in north-western
Ethiopia: a MSF supported health centre in Abdurafi,
Amhara Region and a hospital in Humera, Tigray Region.
The populations included residents as well as high num-
bers of migrant workers who were present seasonally.
Inclusion criteria
All clients, aged > = 5 years, presenting to be tested for
HIV in the study sites were offered participation in the
study. All study participants underwent informed con-
sent procedures and had a written consent form signed
by the participant or the guardian.
Sample size
A sample size of 200 KHB positive and 200 KHB negative
participants was chosen based on the WHO guidance for
evaluation of RDTs [11]. To achieve the sample, all KHB
positive samples were included along with every 10th KHB
negative sample until a minimum of 200 positive samples
was reached. In order to increase power for the secondary
objective on VL, additional participants were recruited
until a total of 90 individuals with VL were included.
Dilution testing was performed on the total sample set.
Testing
Initial testing was done at the Counselling and Testing
(CT) centres. Laboratory technicians, blinded to the CT
results, re- tested each sample on plasma with the 3
RDTs in the national algorithm (KHB, STAT-PAK® and
Unigold™). Tests were performed according to manu-
facturer’s instructions and invalid tests discarded and
repeated on new test devices. All samples underwent
testing by Western Blot (WB) with technicians blinded
to earlier results using MP Diagnostics HIV Blot 2.2.
Interpretation of results was based on American Red
Cross recommendations [12].
Samples indeterminate on WB were repeated and if
still indeterminate, underwent DNA PCR examination
using Roche Amplicor DNA v1.5 on dry blood spots
(DBS) at the Ethiopian Health and Nutrition Research
Institute (EHNRI) laboratory based in Addis Ababa.
Global Clinical and Viral Laboratory in South Africa
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provided quality control for PCR by repeating the sam-
ples to confirm results using the Cobas AmpliPrep/
Cobas TaqMan HIV-1 Qual test. Samples were sent as
dry blood spots (DBS) by international courier, packaged
in accordance with IATA regulations for such samples.
Where results between the two labs were discrepant, the
result from South Africa was used.
The final gold standard result was that of Western Blot,
and where Western Blot was indeterminate, the PCR result.
Dilution technique
Patient plasma was diluted with seronegative plasma
from healthy blood donors using a micropipette and
microtitration plate. Plasma was defined as seronegative
when negative on 2 RDTs and on WB. 10 μL of patient
plasma was first diluted 1:10 in 90 μL of negative plasma.
This was followed by a serial 4-fold dilution from 1:10 to
1:10,240 in negative plasma.
Testing was performed on Determine™ HIV-1/2 (Alere
Laboratories, Japan) using 50 L of diluted sample and
read within 15 minutes following manufacturer’s instruc-
tions. Tests were interpreted as positive if there was any
colouration of the test line. The highest dilution that
gave a positive result was recorded. Where the lowest
dilution (1/10) was negative, the sample was reported as
negative. Invalid tests, where the control line did not
appear, were discarded and repeated on a new test de-
vice according to manufacturers’ instructions.
Quality control
All staff underwent training on the study standard oper-
ating procedures by the MSF laboratory supervisor, and
received regular monitoring and supervision.
Analysis
Predictive values and sensitivity and specificity were esti-
mated from the 2 × 2 table of observed results after
weighting based on the sampling proportion of the KHB
positive and negative samples. Confidence intervals for
each of the test parameters were calculated using exact
binomial intervals.
The proportion of total specimens with the same classi-
fication measured concordance between the gold standard
and experimental methodology. The kappa statistic was
calculated to assess agreement. Statistical analysis was
done using Stata version 12 (StataCorp, College Station,
Texas, USA).
Ethical review
The study received approval from the MSF Ethics
Review Board, the Ethiopian Health and Nutrition Research
Institute Research and Ethical Clearance Committee, and
the National Research Ethics Review Committee, Ministry
of Science and Technology in Ethiopia.
Results
2897 individuals were recruited to the study. One sam-
ple was excluded due to missing WB/PCR results, and a
duplicate was dropped, giving a total of 2895 in the final
analysis. 495 were selected for testing by dilution and
with the gold standard. 247 were positive on the gold
standard for a prevalence of 8.5 % (247/2895).
The serial KHB/STAT-PAK® algorithm correctly
identified 247 positives, yielded one false positive and
no false negatives for a sensitivity of 100 % (95 % CI:
98.5-100), specificity of 100 % (95 % CI: 99.8-100),
negative predictive value (NPV) of 100 % (95 % CI:
98.5-100) and positive predictive value (PPV) of 99.6 %
(95 % CI: 97.8-100).
The tiebreaker KHB/STAT-PAK® /Unigold™ algorithm
correctly identified 247 positives, yielded 18 false posi-
tives, and no false negatives for a sensitivity of 100 %
(95 % CI: 98.5-100), specificity of 99.3 % (95 % CI: 98.9-
99.6), NPV of 100 % (95 % CI: 98.4-100) and PPV of
93.2 % (95 % CI: 89.5-95.9).
Results of dilution testing
Results for the performance of each dilution can be
found in Tables 1–2. The 1/40 dilution correctly identi-
fied 247 positives and 246 negatives, and had two false
positives. The 1/160 dilution correctly identified 246
positives and 248 negatives with no false positives, one
false negative, while the 1/640 dilution had no false posi-
tives and 3 false negatives.
The sensitivity of the 1/160 dilution was 99.6 % (95 % CI:
97.8-100) with a NPV of 100 % (95 % CI: 99.8-100) and a
specificity and PPV of 100 % (95 % CI: 98.5-100).
Concordance between the dilution test and the gold
standard of WB resolved by PCR is shown in Table 1.
Concordance of the best performing dilution, 1/160,
with WB alone was 87.15 % (kappa = 0.771). Excluding
the 64 WB indeterminate results gave 100 % concord-
ance (kappa = 1.0).
Incorporating the dilution tests into the tiebreaker
algorithm improved the specificity and PPV at the lower
dilutions of 1/10 and 1/40. Complete results are shown
in Tables 3–4.
Results on discordant RDTs
The serial algorithm KHB/STAT-PAK® had 24 discordant
results, all of which were resolved negative. The 1/40
strength misidentified one discordant as positive whereas
the 1/10 dilution had 3 false positives. The higher dilu-
tion strengths from 1/160 and up were able to correctly
identify all 24 as negative. An alternate serial KHB/
Unigold™ algorithm had 9 discordant results, 2 of which
were positive on gold standard. All dilution strengths
correctly identified all 9 discordants.
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Discussion
The dilution test was able to correctly identify all 18
false positive results at a level of 1/160 with a specificity
of 100 %. However the improved specificity came at a
cost of sensitivity, as the sensitivity worsened with in-
creasing dilutions.
To further understand the sensitivity of the new meth-
odology, we examined the false negative results at lower
dilutions to determine if they were more likely to be due
to early seroconversion or to poor sensitivity of the dilu-
tion test. One gold standard positive sample tested posi-
tive at a dilution of 1/40 but negative at 1/160. This
sample had a weakly positive test line on all 3 RDTs, an
indeterminate result on WB (+gp160, +p24) and a posi-
tive result on PCR. This individual was tested due to
presence of a sexually transmitted infection and listed
the most recent exposure as 19 days prior to testing.
CD4 was 428. This sample was suggestive of seroconver-
sion. There were 2 additional false negative results at the
dilution level of 1/640. One was positive on KHB and
Unigold™, weakly reactive for STAT-PAK®, and positive
on WB. Reason for testing was risk of exposure with
most recent exposure 11 days prior to testing. CD4 was
260. The second sample was positive on all 3 RDTs, WB
and PCR. Reason for testing was pre-marriage screening
and no exposure risk was listed. CD4 was 647. Both of
these samples were unlikely to be seroconversion. More
data is needed, however this suggests that occasional
true positive samples with established HIV infection will
be misclassified by dilution. This is relevant, as instruct-
ing the patient to return to be re-tested after several
weeks as is done now when early seroconversion is sus-
pected, may not correctly resolve these false negatives.
Given the risk of false negative results with the dilu-
tion test, we conclude that the dilution test cannot re-
place WB as a confirmation test. However its ability to
differentiate false positives from true positives, suggests
that it has potential to be used as a supplementary test
in a confirmatory algorithm where RDT algorithm posi-
tive samples are confirmed with dilution, and negative
dilution samples are referred to a higher-level laboratory
for NAT. The referral for NAT is facilitated by the re-
cently increased availability of PCR testing on dried
blood spots for infant testing.
Comparison with existing supplementary tests
The performance of dilution as a supplementary test
compares well to published evaluations of both Multi-
Table 1 Results of the dilution test compared to gold standard (N = 495)
Dilution Result Number Number with gold standard result Concordance Kappa value*
Positive (%) Negative (%)
1/10 Positive 259 247 (95.3) 12 (4.6) 97.6 0.952
Negative 236 0 236 (100)
1/40 Positive 249 247 (99.2) 2 (0.8) 99.6 0.992
Negative 246 0 246 (100)
1/160 Positive 246 246 (100) 0 99.8 0.996
Negative 249 1 (0.4) 248 (99.6)
1/640 Positive 244 244 (100) 0 99.4 0.988
Negative 251 3 (1.2) 248 (98.8)
1/2560 Positive 240 240 (100) 0 98.6 0.972
Negative 255 7 (2.8) 248 (97.2)
1/10,240 Positive 221 221 (100) 0 94.8 0.895
Negative 274 26 (9.5) 248 (90.5)
TOTAL 495 247 (49.9) 248 (50.1)
*All p values for the kappa statistics are <0.001
Table 2 Performance characteristics of the dilution test compared to gold standard (N = 2895)
Dilution Sensitivity (95 % CI) Specificity (95 % CI) PPV (95 % CI) NPV (95 % CI)
1/10 100 % (98.5-100) 96.3 % (95.5-97.0) 71.6 % (66.5-76.3) 99.6 % (98.5-100)
1/40 100 % (98.5-100) 99.5 % (99.2-99.7) 95.1 % (91.6-97.3) 100 % (98.5-100)
1/160 99.6 % (97.8-100) 100 % (98.5-100) 100 % (98.5-100) 100 % (99.8-100)
1/640 98.8 % (96.5-99.8) 100 % (98.5-100) 100 % (98.5-100) 99.9 % (99.7-100)
1/2560 97.2 % (94.3-98.9) 100 % (98.5-100) 100 % (98.5-100) 99.7 % (99.5-99.9)
1/10,240 89.5 % (85.0-93.0) 100 % (98.5-100) 100 % (98.3-100) 99.0 % (98.6-99.4)
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spot and Geenius. An American study of Multispot in
an algorithm with Architect 4th generation immunoassay
showed that Multispot identified a similar proportion of
true positives as Western Blot, 93.7 % versus 94.4 %
[13]. There were 90 (13.8 %) samples that were positive
on the screening assay and negative on Multispot. These
were resolved by NAT, to reveal 47.8 % were false posi-
tives on the screening assay and 52.2 % were early sero-
conversion. A Canadian study compared Multispot with
Geenius on a panel of samples [14]. Sensitivity for both
was 100 %, however specificity was 99.1 % for Multi-
spot and 96.3 % for Geenius (p = 0.688). Kappa value for
agreement between the two tests was 0.96 (0.92-0.99).
An ideal confirmation test for resource limited settings
would be low cost, simple and rapid, robust in terms of
temperature and environmental conditions, with both
high sensitivity and specificity and few indeterminate re-
sults. The dilution test uses RDTs that are commonly
available in sites doing HIV testing. It requires less skill
than the WB, and is similar in skill level to that of the
OIC as it also requires precise pipetting techniques. In
most cases, only 2 dilutions need to be tested, giving a
cost of approximately $3 USD and a turnaround time of
30–40 minutes. This compares to 2 hours for the OIC,
15 minutes for the Multi-spot and 3 hours for WB. An
advantage is that there are no indeterminate results, as
with OIC, Multi-spot and WB. Indeterminate results are
undesirable, as they require individuals to come back for
further testing with the attendant risk of failure to follow
up. The dilution test can not be used to definitively rule
out HIV infection due to the risk of false negatives and
requires all negative results to be tested with NAT.
However for the majority of screen positive samples,
same day results would be available. In our cohort, using
the tiebreaker algorithm presently in use in Ethiopia, this
would mean 246 of 265 (92.8 %) screen positives could
be immediately confirmed at a dilution of 1/160, while
19 would go on to further testing to ultimately identify
18 false positives. In other words, one positive sample
would be unnecessarily subjected to an additional test. A
dilution of 1/640 would result in 244/265 (92.1 %) posi-
tives immediately confirmed, and 21 sent for NAT.
Table 3 Results of KHB/STAT-PAK®/Unigold™ tiebreaker algorithm with dilution as a supplementary test compared to gold standard
(N = 495)
Algorithm Result Number Number with gold standard result Concordance Kappa value*
Positive (%) Negative (%)
1/10 Positive 251 247 (98.4) 4 (1.6) 99.2 % 0.984
Negative 244 0 244 (100)
1/40 Positive 248 247 (99.6) 1 (0.4) 99.8 % 0.996
Negative 247 0 247 (100)
1/160 Positive 246 246 (100) 0 99.8 % 0.996
Negative 249 1 (0.4) 248 (99.6)
1/640 Positive 244 244 (100) 0 99.4 % 0.988
Negative 251 3 (1.2) 248 (98.8)
1/2560 Positive 240 240 (100) 0 98.6 % 0.972
Negative 255 7 (2.8) 248 (97.3)
1/10,240 Positive 221 221 (100) 0 94.8 % 0.895
Negative 274 26 (9.5) 248 (90.5)
TOTAL 495 247 (49.9) 248 (50.1)
*All p values for the kappa statistics are <0.001
Table 4 Performance characteristics of the KHB/STAT-PAK®/Unigold™ tiebreaker algorithm with dilution as a supplementary test
compared to gold standard (N = 2895)
Dilution Sensitivity (95 % CI) Specificity (95 % CI) PPV (95 % CI) NPV (95 % CI)
1/10 100 % (95.8-100) 99.9 % (99.6-100) 98.4 % (96.0-99.6) 100 % (98.5-100)
1/40 100 % (98.5-100) 100 % (99.8-100) 99.6 % (97.8-100) 100 % (98.5-100)
1/160 99.6 % (97.8-100) 100 % (98.5-100) 100 % (98.5-100) 100 % (99.8- 100)
1/640 98.8 % (96.5-99.8) 100 % (98.5-100) 100 % (98.5-100) 99.9 % (99.7-100)
1/2560 97.2 % (94.3-98.9) 100 % (98.5-100) 100 % (98.5-100) 99.7 % (99.5-99.9)
1/10,240 89.5 % (85.0-93.0) 100 % (98.5-100) 100 % (98.3-100) 99.0 % (98.6-99.4)
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The 2013 US diagnostic algorithm emphasizes the
importance of detection of acute HIV infection, and dis-
crimination between HIV 1 & 2. Dilution testing used as
part of a supplementary testing algorithm with NAT,
would identify early seroconversion. Discrimination be-
tween HIV 1 & 2 would not be addressed aside from
that gleaned from discriminatory HIV RDTs. This is a
similar limitation to Western Blot, which is known to be
inaccurate at discriminating between HIV 1 & 2.
Theoretical basis for dilution methodology
Our methodology is based on the principles used to
identify recent HIV infection for the purposes of inci-
dence surveys. Here recent infection versus established
infection is distinguished through an algorithm whereby
samples are tested for HIV with enzyme immunoassays
(EIA) with high sensitivity. Positive samples then go on
to get a second, less sensitive test. The less sensitive test
is an EIA test that is modified by use of a diluted sample
and reduced incubation time. Samples positive on both
tests are determined to be established infection, while
those positive on the sensitive (S) test but negative on
the less sensitive (LS) test are designated recent infec-
tion. This S/LS methodology is based on the principle
that antibody titres increase over a period of several
months after initial infection. Samples with low antibody
titres test negative on EIA when the sample is diluted,
whereas samples with higher titres are persistently posi-
tive [15]. Following on the work of Constantine [16],
Soroka et al. proposed a variation for resource limited
settings, whereby RDTs are substituted for the EIA in
the S/LS algorithm [17]. Here dilution is again used to
alter the sensitivity of the RDTs. A positive result on the
first RDT screening test, followed by a negative RDT
result on the diluted sample suggests recent infection.
This algorithm has been successfully employed in inci-
dence surveys using different RDTs and at differing dilu-
tion levels [18, 19].
Broad spectrum antibodies are produced in the early
immune response to infectious disease antigens and can
cause non-specific cross reactivity in serological testing
[6]. These antibodies are expected to have low avidity, as
has been demonstrated by work in blood donors [20]. In
proposing dilution as a methodology to confirm HIV
infection, we postulate that dilution will distinguish both
the low avidity antibodies, as well as the possibly low
titres [21] of the cross-reacting antibodies responsible
for false reactivity. We found data to support this appli-
cation of dilution testing in a report from Ghana using
Soroka’s methodology to identify incident HIV infection
that describes how acute seroconversion was confused
with false reactivity [22]. 76 samples repeatedly positive
on Genescreen Ultra HIV Ag-Ab ELISA were tested on
Determine™ with the S/LS methodology. 41 were positive
on the sensitive RDT, and of these 18 were positive on di-
lution, while 23 were negative on dilution. Confirmation
with INNO-LIA™ revealed that all 35 Determine™ non-
reactive results were true negatives, and only 1 of 23
samples negative on dilution was HIV positive. All those
positive on dilution were true positives, suggesting that
dilution was able to distinguish the cross reactivity from
true positivity.
Choice of RDT
We chose to use Determine™ as the RDT as it has high
sensitivity and is in common use in many countries. We
also had experience with piloting dilution testing on
Determine™ in the Democratic Republic of Congo and
therefore had programmatic data on its performance.
We diluted samples with normal saline to 1/5000 and
used the OIC confirmation test as the gold standard.
The proportion of agreement with OIC for 263 samples
positive on both Determine™ and Unigold™ was 89.2 %
(kappa 0.423) when indeterminates on OIC were ex-
cluded. The dilution test identified all 23 RDT algorithm
false positives, and introduced 5 false negatives. A limi-
tation is that no NAT was done, so it is possible that
some of the false positives identified on gold standard
were in fact early seroconversion.
Use of dilution with RDT discordant samples
Finally, an unexpected finding in our study was the
ability of dilution testing at a level of 1/160 to correctly
resolve all 33 RDT discordant results from the serial
algorithms in our study. Discordant results occur when
one RDT is positive and the other negative on a serial or
parallel algorithm. They are undesirable because they re-
sult in an inconclusive result for the client that requires
re-testing in two weeks [1]. National programmes often
use a tiebreaker algorithm to avoid these inconclusive
results with their attendant risk of loss to follow up des-
pite the known high risk of false positives results with
the tiebreaker algorithm [2, 9, 23, 24]. Our results sug-
gest that dilution testing has the potential to immedi-
ately confirm positive results and to allow a preliminary
negative result to be given to clients with discordant
RDT results. Discordant samples negative on dilution
would still require follow up testing in two weeks and/or
referral for NAT. Further formal study is needed to ex-
plore this potential role for dilution testing in resolving
discordant RDT results.
Limitations
The strength of our study is that NAT testing was avail-
able to resolve indeterminate WB samples which made
it possible to rule out early seroconversion as a poten-
tial cause of false positive results. It is limited by its
application in a single cohort in Ethiopia with a single
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RDT. More work is needed to determine whether our
results are replicable in other locations and with other
RDTs. In addition, each site using dilution as a supple-
mentary test would need to establish an appropriate di-
lution cut-off prior to using the test. The methodology
would be similar to what has been used in incidence
surveys [17].
Conclusion
Our study is a first step in providing proof of concept
for a new, cost effective method of confirming HIV diag-
nosis in resource-limited settings. It has potential for use
as a supplementary test in a confirmatory algorithm,
whereby double positive RDT results are tested by dilu-
tion, with positive results confirming HIV infection.
Negative dilution results would require NAT testing to
rule out false negative results either due to seroconver-
sion or misclassification by the lower sensitivity dilution
test. Further research is needed to determine if our re-
sults can be replicated in other settings.
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